Healthcare provider profile · identity verified

John Fontenot, MD

Family Practice · BRIGHTON, CO · NPI 1033373410

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	225	70
Lisinopril	Lisinopril	175	44
Levothyroxine Sodium	Levothyroxine Sodium	137	31
Amlodipine Besylate	Amlodipine Besylate	100	26
Omeprazole	Omeprazole	83	19
Albuterol Sulfate Hfa	Albuterol Sulfate	81	27
Hydrochlorothiazide	Hydrochlorothiazide	80	29
Metformin Hcl	Metformin Hcl	80	25
Gabapentin	Gabapentin	78	27
Metformin Hcl Er	Metformin Hcl	76	25
Tamsulosin Hcl	Tamsulosin Hcl	73	18
Fluticasone Propionate	Fluticasone Propionate	68	19
Losartan Potassium	Losartan Potassium	68	25
Furosemide	Furosemide	63	20
Trazodone Hcl	Trazodone Hcl	55	18
Meloxicam	Meloxicam	49	15
Jardiance	Empagliflozin	48	11
Famotidine	Famotidine	44	14
Montelukast Sodium	Montelukast Sodium	40	suppressed
Simvastatin	Simvastatin	40	11
Pregabalin	Pregabalin	39	suppressed
Alendronate Sodium	Alendronate Sodium	38	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	38	suppressed
Duloxetine Hcl	Duloxetine Hcl	37	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	37	13
Sertraline Hcl	Sertraline Hcl	36	11
Carvedilol	Carvedilol	35	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	34	suppressed
Baclofen	Baclofen	33	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	29	suppressed
Trulicity	Dulaglutide	29	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	28	suppressed
Ozempic	Semaglutide	27	suppressed
Xarelto	Rivaroxaban	27	suppressed
Finasteride	Finasteride	26	suppressed
Glipizide	Glipizide	25	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	25	11
Diclofenac Sodium	Diclofenac Sodium	23	suppressed
Spiriva Handihaler	Tiotropium Bromide	23	suppressed
Tizanidine Hcl	Tizanidine Hcl	23	suppressed
Tramadol Hcl	Tramadol Hcl	23	suppressed
Clopidogrel	Clopidogrel Bisulfate	22	suppressed
Prednisone	Prednisone	22	16
Potassium Chloride	Potassium Chloride	21	suppressed
Spironolactone	Spironolactone	21	suppressed
Eliquis	Apixaban	20	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	20	suppressed
Spiriva Respimat	Tiotropium Bromide	19	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	19	suppressed
Symbicort	Budesonide/Formoterol Fumarate	18	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	17	suppressed
Ibuprofen	Ibuprofen	17	suppressed
Levetiracetam	Levetiracetam	17	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	17	suppressed
Ventolin Hfa	Albuterol Sulfate	17	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	17	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	16	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Metoprolol Succinate	Metoprolol Succinate	16	suppressed
Ondansetron Hcl	Ondansetron Hcl	16	suppressed
Buspirone Hcl	Buspirone Hcl	15	suppressed
Celecoxib	Celecoxib	15	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	15	suppressed
Linzess	Linaclotide	15	suppressed
Farxiga	Dapagliflozin Propanediol	13	suppressed
Lamotrigine	Lamotrigine	13	suppressed
Lidocaine	Lidocaine	13	suppressed
Methocarbamol	Methocarbamol	13	suppressed
Propranolol Hcl Er	Propranolol Hcl	13	suppressed
Allopurinol	Allopurinol	12	suppressed
Atenolol	Atenolol	12	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	12	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	12	suppressed
Stiolto Respimat	Tiotropium Br/Olodaterol Hcl	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Mounjaro	Tirzepatide	11	suppressed
Naproxen	Naproxen	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Pravastatin Sodium	Pravastatin Sodium	11	suppressed
Rizatriptan	Rizatriptan Benzoate	11	suppressed
Tradjenta	Linagliptin	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error